June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Mesenchymal stem cell based therapy for restoring corneal graft transparency
Author Affiliations & Notes
  • Vijayalakshmi Rajendran
    Immunity, Infection and Inflammation, University of Aberdeen, Aberdeen, United Kingdom
  • Rosie Fordyce
    Immunity, Infection and Inflammation, University of Aberdeen, Aberdeen, United Kingdom
  • Izabela Klaska
    Immunity, Infection and Inflammation, University of Aberdeen, Aberdeen, United Kingdom
  • John V Forrester
    Immunity, Infection and Inflammation, University of Aberdeen, Aberdeen, United Kingdom
    Immunology and Virology, University of Western Australia, Crawley, WA, Australia
  • May Griffith
    Integrative Regenerative Medicine Centre, Linköping University, Linköping, Sweden
  • Lucia Kuffova
    Immunity, Infection and Inflammation, University of Aberdeen, Aberdeen, United Kingdom
  • Footnotes
    Commercial Relationships Vijayalakshmi Rajendran, None; Rosie Fordyce, None; Izabela Klaska, None; John Forrester, None; May Griffith, None; Lucia Kuffova, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4873. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Vijayalakshmi Rajendran, Rosie Fordyce, Izabela Klaska, John V Forrester, May Griffith, Lucia Kuffova; Mesenchymal stem cell based therapy for restoring corneal graft transparency. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4873.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Mesenchymal stem cells (MSC) are being extensively tested in the field of organ transplantation due to their potent anti-inflammatory and tissue regenerative properties. In the case of corneal transplantation, the additional anti-angiogenic properties of MSC make them an attractive candidate for maintaining corneal clarity. This project aims to investigate the effect of allogeneic vs syngeneic MSC in preventing loss of and/or restoring corneal graft clarity in mouse corneal allograft model

Methods: Recipient-derived (syngeneic-Balb/c) and donor-derived (allogeneic-B6) bone marrow MSC were isolated, depleted of CD45+ cells and characterized as lineage negative. The effect of MSC on in vitro T cell proliferation was assessed by CFSE labelling. MSC(1x106 cells) were administered in vivo either intravenously (IV) or subconjuctivally (SC) 7 days before (1st dose) and on the day (2nd dose) of corneal allotransplantation (B6 to Balb/c). Corneal graft opacity was evaluated for 2 months post grafting. Calcein/CFSE labelled MSC were administered IV to determine where MSC trafficked after inoculation. In addition, in vivo induction of T regulatory cells (Tregs) in secondary lymphoid organs was assessed by flow cytometry

Results: Both allo and syn-MSC had strong inhibitory effects on T cell proliferation in vitro. Only IV administered allo-MSC significantly reduced corneal opacification (p<0.0001) compared to syn-MSC and untreated (PBS) controls at 2 months post-transplant. Calcein/CFSE labelled splenocytes were tracked to the spleen and the eye-draining lymph nodes 16 hrs after inoculation by both IV and SC routes. However, labelled MSC could not be detected when administrated IV. Flow cytometric analysis at day 4 after IV showed syn-MSC but not allo-MSC induce significantly higher frequency of splenic Tregs (CD4+ Foxp3+) compared to PBS treated controls (n=4/group)

Conclusions: Our data show that IV but not SC administration of allo-MSC significantly improved corneal allograft survival. Syn-MSC were not effective. This data suggest that allo-MSC induce immunological tolerance to corneal allograft. However the effect did not correlate with induction of Tregs. In addition, the inability to track MSC after IV inoculation suggests that they are rapidly removed from the system presumably by phagocytic engulfment. Engulfment of apoptotic allo-MSC may be a possible mechanism for inducing allospecific tolerance in this model

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×